Vetmedin

Myxomatous mitral valve disease (MMVD) is the most common heart disease in dogs and is seen most often in small-breed dogs over 5 years of age, particularly those weighing under 40 pounds. Any dog can develop heart disease, but some breeds may be at increased risk, including Cavalier King Charles Spaniel, Dachshund, Chihuahua, Welsh Terrier, Fox Terrier, Poodle, Papillon, and Miniature Schnauzer.

VETMEDIN® supports dogs through approved stages of heart disease.

• Early-Stage Treatment: VETMEDIN® Chewable Tablets and VETMEDIN® Solution are the only medications approved by the FDA to delay congestive heart failure (CHF) in dogs with Stage B2 myxomatous mitral valve disease (MMVD). When used as directed before dogs have symptoms, VETMEDIN® gives your dog more symptom-free days.
• Later-Stage Treatment: For dogs that have progressed into heart failure, treatment with VETMEDIN® Chewable Tablets and VETMEDIN® Solution have been demonstrated to extend survival time and improve quality of life.

VETMEDIN® is available as both a liquid solution and chewable tablets, so you can give your dog just the right dose in a formulation that works for them.

• VETMEDIN® Solution (pimobendan oral solution): The only brand to offer an oral solution that's flavorless for dogs who prefer a liquid medication.
• VETMEDIN® (pimobendan) Chewable Tablets: beef-flavored and half-scored for dogs who prefer chews.